{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:24:23Z","timestamp":1789932263113,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"crossref","award":["111-S0033"],"award-info":[{"award-number":["111-S0033"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["105-2320-B-002-052-MY3, MOST 108-2320-B-002-051-MY3, MOST 111-2740-B-002-004, NSTC 112-2740-B-002-002"],"award-info":[{"award-number":["105-2320-B-002-052-MY3, MOST 108-2320-B-002-051-MY3, MOST 111-2740-B-002-004, NSTC 112-2740-B-002-002"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tissue factor (TF)-rich cancer microvesicles are correlated with thrombosis risk. Intrinsic coagulation factors are also associated with the risk of thrombosis in cancer patients. This study explored the roles of pancreatic cancer-derived microvesicles and intrinsic factors in thrombogenesis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Human pancreatic cancer cell lines rich in TF (AsPC-1-TF<jats:sup>high<\/jats:sup>, MIAPaCa-2-TF<jats:sup>high<\/jats:sup>) or poor in TF [AsPC-1-TF<jats:sup>KO<\/jats:sup>(knockout) and MIAPaCa-2-TF<jats:sup>low<\/jats:sup>] were generated for microvesicle preparation and injected into coagulation-defective mice. Inferior vena cava (IVC) clots and lung thrombosis were evaluated. Immunodeficient hemophilia A (NSG-HA) mice were orthotopically injected with the cells mentioned above, and the tumor and IVC clot weights were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>With the injection of TF<jats:sup>high<\/jats:sup> microvesicles, IVC clots were rarely found in hemophilic mice. The TF<jats:sup>low<\/jats:sup> and TF<jats:sup>KO<\/jats:sup> microvesicles resulted in few IVC clots in any mouse. Lung thrombosis was substantially reduced in the hemophilic mice infused with any microvesicle type. In orthotopic tumor models, TF<jats:sup>high<\/jats:sup> cells grew faster than did TF<jats:sup>low<\/jats:sup> cells. TF<jats:sup>high<\/jats:sup> tumor-bearing NSG-WT mice had the most enormous IVC clots, whereas NSG-HA mice had no IVC clots.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Pancreatic cancer thrombosis induced by TF-expressing microvesicles strongly depended on FVIII and FIX, while VWF played a minor role. Moreover, TF, but not FVIII, was significantly related to tumor growth.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12959-025-00715-x","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:21:46Z","timestamp":1744363306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-019X","authenticated-orcid":false,"given":"Sheng-Chieh","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yeh","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2011Hsueh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Rung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wern-Cherng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Tsu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-5581","authenticated-orcid":false,"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"715_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"key":"715_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horvath-Puho E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, Buller HR, Sorensen HT. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959\u201369.","journal-title":"Blood"},{"key":"715_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8:11.","journal-title":"Nat Rev Dis Primers"},{"key":"715_CR4","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137.","journal-title":"Blood"},{"key":"715_CR5","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.","journal-title":"PLoS Med"},{"key":"715_CR6","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","volume":"116","author":"C Ay","year":"2010","unstructured":"Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377\u201382.","journal-title":"Blood"},{"issue":"Suppl 2","key":"715_CR7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","volume":"133","author":"AA Khorana","year":"2014","unstructured":"Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014;133(Suppl 2):S35\u201338.","journal-title":"Thromb Res"},{"key":"715_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-030-20315-3_4","volume":"179","author":"J Roopkumar","year":"2019","unstructured":"Roopkumar J, Khorana AA. Risk of thrombosis in cancer: clinical factors and role of primary prophylaxis. Cancer Treat Res. 2019;179:55\u201368.","journal-title":"Cancer Treat Res"},{"key":"715_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jfma.2021.04.025","volume":"121","author":"SC Chou","year":"2022","unstructured":"Chou SC, Pai CH, Lin SW, Tien HF. Incidence and risk factors for venous thromboembolism in a cohort of Taiwanese patients with lung, gastric, pancreatic cancers or lymphoma. J Formos Med Assoc. 2022;121:360\u20136.","journal-title":"J Formos Med Assoc"},{"key":"715_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","volume":"130","author":"Y Hisada","year":"2017","unstructured":"Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130:1499\u2013506.","journal-title":"Blood"},{"key":"715_CR11","doi-asserted-by":"publisher","first-page":"100123","DOI":"10.1016\/j.rpth.2023.100123","volume":"7","author":"Y Hisada","year":"2023","unstructured":"Hisada Y, Mackman N. Mechanisms of cancer-associated thrombosis. Res Pract Thromb Haemost. 2023;7:100123.","journal-title":"Res Pract Thromb Haemost"},{"key":"715_CR12","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","volume":"13","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870\u20135.","journal-title":"Clin Cancer Res"},{"key":"715_CR13","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","volume":"6","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N, Taubman MB. Plasma tissue factor May be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008;6:1983\u20135.","journal-title":"J Thromb Haemost"},{"key":"715_CR14","doi-asserted-by":"crossref","unstructured":"Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, Iyer RV. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013.","DOI":"10.1016\/j.thromres.2013.06.026"},{"key":"715_CR15","doi-asserted-by":"crossref","unstructured":"Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013.","DOI":"10.1182\/blood-2013-04-460139"},{"key":"715_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/jth.13002","volume":"13","author":"GM Thomas","year":"2015","unstructured":"Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD. Tissue factor expressed by Circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost. 2015;13:1310\u20139.","journal-title":"J Thromb Haemost"},{"key":"715_CR17","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/jth.13809","volume":"15","author":"Y Hisada","year":"2017","unstructured":"Hisada Y, Ay C, Auriemma AC, Cooley BC, Mackman N. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost. 2017;15:2208\u201317.","journal-title":"J Thromb Haemost"},{"key":"715_CR18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1055\/s-0037-1616744","volume":"86","author":"MZ Wojtukiewicz","year":"2001","unstructured":"Wojtukiewicz MZ, Rucinska M, Zacharski LR, Kozlowski L, Zimnoch L, Piotrowski Z, Kudryk BJ, Kisiel W. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost. 2001;86:1416\u201320.","journal-title":"Thromb Haemost"},{"key":"715_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1055\/s-0040-1722193","volume":"121","author":"Y Hisada","year":"2021","unstructured":"Hisada Y, Moser B, Kawano T, Revenko AS, Crosby JR, Spronk HM, Mackman N. The intrinsic pathway does not contribute to activation of coagulation in mice bearing human pancreatic tumors expressing tissue factor. Thromb Haemost. 2021;121:967\u201370.","journal-title":"Thromb Haemost"},{"key":"715_CR20","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1182\/bloodadvances.2021005116","volume":"5","author":"YJ Shim","year":"2021","unstructured":"Shim YJ, Chatterjee V, Swaidani S, Alluri RK, Kundu S, Merkulova A, Angelini D, You D, Whitney SA, Feener EP, et al. Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. Blood Adv. 2021;5:4741\u201351.","journal-title":"Blood Adv"},{"key":"715_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Buller HR, Raskob GE, Weitz JI, Investigators A-T. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609\u201317.","journal-title":"N Engl J Med"},{"key":"715_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323:130\u20139.","journal-title":"JAMA"},{"key":"715_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Investigators F-AT: factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232\u201340.","journal-title":"N Engl J Med"},{"key":"715_CR24","unstructured":"Kalinin DV. Factor XII(a) inhibitors: a review of the patent literature. Expert Opin Ther Pat 2021:1\u201322."},{"key":"715_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jth.15126","volume":"19","author":"JC Fredenburgh","year":"2021","unstructured":"Fredenburgh JC, Weitz JI. New anticoagulants: moving beyond the direct oral anticoagulants. J Thromb Haemost. 2021;19:20\u20139.","journal-title":"J Thromb Haemost"},{"key":"715_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/10408360600966753","volume":"44","author":"M Franchini","year":"2008","unstructured":"Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci. 2008;44:115\u201349.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"715_CR27","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMra1601561","volume":"375","author":"FWG Leebeek","year":"2016","unstructured":"Leebeek FWG, Longo DL, Eikenboom JCJ. Von Willebrand\u2019s disease. N Engl J Med. 2016;375:2067\u201380.","journal-title":"N Engl J Med"},{"key":"715_CR28","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1182\/blood-2014-04-569392","volume":"124","author":"J Chen","year":"2014","unstructured":"Chen J, Zhou H, Diacovo A, Zheng XL, Emsley J, Diacovo TG. Exploiting the kinetic interplay between GPIbalpha-VWF binding interfaces to regulate hemostasis and thrombosis. Blood. 2014;124:3799\u2013807.","journal-title":"Blood"},{"key":"715_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12959-016-0106-0","volume":"14","author":"CT Yen","year":"2016","unstructured":"Yen CT, Fan MN, Yang YL, Chou SC, Yu IS, Lin SW. Current animal models of hemophilia: the state of the Art. Thromb J. 2016;14:22.","journal-title":"Thromb J"},{"key":"715_CR30","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human Hemopoietic stem cells. J Immunol. 2005;174:6477\u201389.","journal-title":"J Immunol"},{"key":"715_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood-2005-02-0516","volume":"106","author":"F Ishikawa","year":"2005","unstructured":"Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. Development of functional human blood and immune systems in NOD\/SCID\/IL2 receptor \u03b3 chainnull mice. Blood. 2005;106:1565\u201373.","journal-title":"Blood"},{"key":"715_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jth.13181","volume":"14","author":"JE Geddings","year":"2016","unstructured":"Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key NS, Wolberg AS, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14:153\u201366.","journal-title":"J Thromb Haemost"},{"key":"715_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2009-08-237719","volume":"115","author":"C Duckers","year":"2010","unstructured":"Duckers C, Simioni P, Spiezia L, Radu C, Dabrilli P, Gavasso S, Rosing J, Castoldi E. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood. 2010;115:879\u201386.","journal-title":"Blood"},{"key":"715_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1160\/TH13-02-0154","volume":"110","author":"CY Kao","year":"2013","unstructured":"Kao CY, Yang SJ, Tao MH, Jeng YM, Yu IS, Lin SW. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo. Thromb Haemost. 2013;110:244\u201356.","journal-title":"Thromb Haemost"},{"key":"715_CR35","doi-asserted-by":"publisher","first-page":"e1835","DOI":"10.1002\/wnan.1835","volume":"15","author":"KP De Sousa","year":"2023","unstructured":"De Sousa KP, Rossi I, Abdullahi M, Ramirez MI, Stratton D, Inal JM. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15:e1835.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"715_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ng0595-119","volume":"10","author":"L Bi","year":"1995","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119\u201321.","journal-title":"Nat Genet"},{"key":"715_CR37","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","volume":"90","author":"HF Lin","year":"1997","unstructured":"Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90:3962\u20136.","journal-title":"Blood"},{"key":"715_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2024.01.019","volume":"235","author":"SC Chou","year":"2024","unstructured":"Chou SC, Yen CT, Yang YL, Chen SH, Wang JD, Fan MN, Chen LF, Yu IS, Tsai DY, Lin KI, et al. Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice. Thromb Res. 2024;235:155\u201363.","journal-title":"Thromb Res"},{"key":"715_CR39","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Zochbauer-Muller S, Preusser M, Pabinger I, Ay C. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137:1669\u201378.","journal-title":"Blood"},{"key":"715_CR40","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","volume":"105","author":"JL Yu","year":"2005","unstructured":"Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734\u201341.","journal-title":"Blood"},{"key":"715_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1373\/clinchem.2009.123695","volume":"55","author":"S Regina","year":"2009","unstructured":"Regina S, Valentin JB, Lachot S, Lemarie E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55:1834\u201342.","journal-title":"Clin Chem"},{"key":"715_CR42","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1055\/s-2007-991531","volume":"33","author":"A Amirkhosravi","year":"2007","unstructured":"Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 2007;33:643\u201352.","journal-title":"Semin Thromb Hemost"},{"key":"715_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-2004-822969","volume":"30","author":"M Patricia","year":"2004","unstructured":"Patricia M, Fernandez PD, Steven R, Patierno PD, Frederick R. Rickles MD: tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30:31\u201344.","journal-title":"Semin Thromb Hemost"},{"key":"715_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000073286","volume":"33","author":"W Ruf","year":"2003","unstructured":"Ruf W. Tissue Factor-Dependent signaling in tumor biology. Pathophysiol Haemost Thromb. 2003;33:28\u201330.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"715_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2008-1079254","volume":"34","author":"F Schaffner","year":"2008","unstructured":"Schaffner F, Ruf W. Tissue factor and Protease-Activated receptor signaling in cancer. Semin Thromb Hemost. 2008;34:147\u201353.","journal-title":"Semin Thromb Hemost"},{"key":"715_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, et al. Edoxaban for the treatment of Cancer-Associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324.","journal-title":"N Engl J Med"},{"key":"715_CR47","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599\u2013607.","journal-title":"N Engl J Med"},{"key":"715_CR48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943\u20139.","journal-title":"Lancet Oncol"},{"key":"715_CR49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, et al. Rivaroxaban for thromboprophylaxis in High-Risk ambulatory patients with cancer. N Engl J Med. 2019;380:720\u20138.","journal-title":"N Engl J Med"},{"key":"715_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711\u20139.","journal-title":"N Engl J Med"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00715-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:38:39Z","timestamp":1744371519000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00715-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00715-x","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}